###begin article-title 0
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">1</xref>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice*1
###end article-title 0
###begin p 1
###xml 52 74 52 74 <email xmlns:xlink="http://www.w3.org/1999/xlink">nader_abraham@nymc.edu</email>
To whom correspondence should be addressed. e-mail: nader_abraham@nymc.edu
###end p 1
###begin p 2
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</bold>
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><bold>Author's Choice</bold> - Final version full access.</italic>
Author's Choice - Final version full access.
###end p 2
###begin p 3
 applies to Author Choice Articles
###end p 3
###begin p 4
###xml 786 787 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
We examined mechanisms by which L-4F reduces obesity and diabetes in obese (ob) diabetic mice. We hypothesized that L-4F reduces adiposity via increased pAMPK, pAKT, HO-1, and increased insulin receptor phosphorylation in ob mice. Obese and lean mice were divided into five groups: lean, lean-L-4F-treated, ob, ob-L-4F-treated, and ob-L-4F-LY294002. Food intake, insulin, glucose adipocyte stem cells, pAMPK, pAKT, CB1, and insulin receptor phosphorylation were determined. Subcutaneous (SAT) and visceral adipose tissue (VAT) were determined by MRI and hepatic lipid content by magnetic resonance spectroscopy. SAT and VAT volumes decreased in ob-L-4F-treated animals compared with control. L-4F treatment decreased hepatic lipid content and increased the numbers of small adipocytes (P < 0.05) and phosphorylation of insulin receptors. L-4F decreased CB1 in SAT and VAT and increased pAKT and pAMPK in endothelium. L-4F-mediated improvement in endothelium was prevented by LY294002. Inhibition of pAKT and pAMPK by LY294002 was associated with an increase in glucose levels. Upregulation of HO-1 by L-4F produced adipose remodeling and increased the number of small differentiated adipocytes. The anti-obesity effects of L-4F are manifested by a decrease in visceral fat content with reciprocal increases in adiponectin, pAMPK, pAKT, and phosphorylation of insulin receptors with improved insulin sensitivity.
###end p 4
###begin p 5
Published, JLR Papers in Press, March 26, 2009.
###end p 5
###begin p 6
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 694 695 694 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 793 793 793 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9"/>
###xml 793 793 793 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10"/>
###xml 793 793 793 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11"/>
###xml 793 793 793 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12"/>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1245 1246 1245 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 396 402 <span type="species:ncbi:9606">humans</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
###xml 1070 1074 <span type="species:ncbi:10090">mice</span>
Insulin resistance is the hallmark of type 2 diabetes and its associated cardiovascular disease (1, 2). Once hyperglycemia is established, an increase in reactive oxygen species (ROS) occurs, resulting in a progressive deterioration in vascular function with an elevation of inflammatory cytokines from adipose tissue (3). Obesity is also a risk factor for cardiovascular disease and diabetes in humans (4). Obesity and insulin resistance are considered independent predictors of cardiovascular disease (5, 6). However, recent studies have revealed the presence of myocardial perfusion abnormalities, even in the absence of coronary lesions, in patients with asymptomatic diabetes mellitus (6, 7). This suggests that obesity and diabetes are strongly associated with endothelial dysfunction (8-13), increased lipolysis, hepatic triglyceride secretion, and sterol-regulatory element binding protein-1 (SREBP-1) (14). SREBPs are the major transcription factors that regulate genes involved in fatty acid and cholesterol synthesis and are regulated by pAMPK and pAKT in ob mice (14). In addition, activation of the endocannabinoid receptor-1 (CB1 receptor) was shown to increase the hepatic lipogenic transcription factor and fatty acid synthesis (7). In visceral adipose tissue, CB1 receptor activity leads to a decrease in adiponectin and an increase in lipogenesis, both of which contribute to insulin resistance.
###end p 6
###begin p 7
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 635 635 635 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17"/>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1060 1062 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1329 1330 1329 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1332 1334 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1334 1334 1334 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21"/>
###xml 1334 1334 1334 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22"/>
###xml 1335 1337 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 1531 1533 1531 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1533 1533 1533 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25"/>
###xml 1534 1536 1534 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
###xml 1160 1164 <span type="species:ncbi:10090">mice</span>
Drug therapy for atherosclerosis, coronary artery disease, dyslipidemia, hypertension, and other diseases associated with highly inflammatory states have been shown to either directly or indirectly induce heme oxygenase (HO) activity and increase HO gene expression (10). These drugs include aspirin, statins, losartan, immunosuppressive agents, such as cyclosporine A, and a host of other compounds, including 4F (10, 15). These 4F compounds are apolipoprotein A1 mimetic peptides, synthesized from either D (D-4F) or L (L-4F) amino acids that enhance the ability of HDL to protect LDL against oxidation in atherosclerotic animals (16-18). Oral administration of D-4F has been reported to reduce atherosclerotic disease independent of cholesterol levels (17, 18). D-4F causes HDL to become anti-inflammatory, stimulates HDL-mediated cholesterol efflux, and reverses cholesterol transport from macrophages (16, 17). D-4F has been reported to reduce SREBP-1c mRNA levels EO6 immunoreactivity and renal inflammation in LDL receptor-null mice fed a Western diet (19). In a sickle cell disease model, apolipoprotein A1 improved vasoreactivity in LDL-receptor null mice (20). L-4F and D-4F improve vascular function and restore the balance between nitric oxide and superoxide anions due to increase in EC-SOD, HO-1, and peNOS levels (8, 20-23). Induction of HO-1 protein results in a marked increase in serum levels of adiponectin and a decrease in the inflammatory cytokines IL-1, IL-6, and TNF and an increase in insulin sensitivity (24-26).
###end p 7
###begin p 8
In this study, we examined the mechanism of L-4F treatment in the restoration of vascular function by measuring the expression of pAMPK, pAKT, and insulin receptor phosphorylation. L-4F treatment resulted in reduced adiposity, manifested by a decrease in visceral and subcutaneous fat levels, decreased adipogenesis, and the increased presence of smaller insulin sensitive adipocytes via an increase in pAMPK, pAKT, and insulin receptor phosphorylation.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
Animal protocols
###end title 10
###begin p 11
###xml 674 675 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 694 695 686 687 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 733 735 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1627 1629 1616 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 1631 1633 1620 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1725 1727 1714 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1881 1882 1870 1871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1890 1891 1879 1880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1904 1905 1893 1894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1928 1929 1917 1918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1943 1944 1932 1933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1959 1960 1948 1949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">Mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
###xml 442 446 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 1123 1128 <span type="species:ncbi:10090">mouse</span>
###xml 1214 1218 <span type="species:ncbi:10090">mice</span>
###xml 1287 1291 <span type="species:ncbi:10090">mice</span>
###xml 1766 1770 <span type="species:ncbi:10090">mice</span>
###xml 2014 2018 <span type="species:ncbi:10090">mice</span>
Male obese (ob) mice (B6v-Lep ob/J) were purchased from Harlan (Chicago, IL) at the age of 7 weeks and used at 8 weeks of age. Age- and sex-matched lean mice (B6.V, lean; Harlan) served as controls. Mice were fed a normal chow diet and had free access to water. Body weight of ob and lean mice at the beginning of the treatment were 34 +/- 5 g and 26 +/- 3 g, respectively. Glucose levels were 248 +/- 21 and 126 +/- 14 mg/dl for ob and lean mice, respectively. Glucose monitoring was performed using an automated analyzer (Life Scan, Milpitas, CA). Beginning at 9 weeks of age when all ob mice had established diabetes, L-4F (i.e., Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2) synthesized from l-amino acids as previously described (27) was injected at a dose of 200 mug/100 g daily in 200 mul vehicle), or vehicle (ABCT: ammonium bicarbonate buffer at pH 7.4 containing 0.01% Tween 20) were administered intraperitoneally (i.p.) for 6 weeks. At the time of sacrifice, subcutaneous and visceral fat visible in the abdomen, mesenteric fat, fat around the liver, kidney spleen, and heart were dissected free, pooled for each mouse, and weighed. Blood was collected (50-100 mul) from the tail vein of anesthetized ob mice following administration of either L-4F or vehicle. L-4F treated ob mice were divided into two groups, one treated with L-4F and the P13 kinase AKT inhibitor, LY294002 (Cell Signaling Technology, Boston, MA) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-HCl), which was dissolved in DMSO and diluted with PBS and injected i.p. at a dose of 100 mg/kg, three times a week for the last three weeks of the study (28, 29). We have previously shown that LY294004 is an inhibitor of HO-1-mediated cell protection (30). The second group of ob-L-4F-treated mice were treated with the same volume of vehicle (PMSO+PBS) without LY294002. Six groups of animals were studied: A) lean, B) lean-L-4F, C) lean-L-4F-LY-294002, D) ob control, E) ob-L-4F, and F) ob-L-4F-LY294002. Food intake did not change in the mice in any treatment group. The Animal Care and Use Committee of New York Medical College approved all experiments.
###end p 11
###begin title 12
MRI and magnetic resonance spectroscopy
###end title 12
###begin p 13
###xml 575 577 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 577 577 575 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32"/>
###xml 578 580 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 159 163 <span type="species:ncbi:10090">Mice</span>
###xml 390 395 <span type="species:ncbi:10090">mouse</span>
Subcutaneous fat tissue (SAT) and visceral fat tissue (VAT) were determined by MRI, while hepatic fat was determined by magnetic resonance spectroscopy (MRS). Mice were imaged in a GE Excite 1.5T scanner using a knee coil with a T1-weighted spin-echo pulse sequence (TEC 9.0 ms, TR = 540ms, NEX = 4, FOVO 8 x 8 cm) and an image size of 224 x 192 pixels. The whole chest and abdomen of each mouse were covered with axial slices (thickness 3 mm, no spacing). Acquired images underwent semiautomatic segmentation of SAT and VAT using the previously validated HIPPO FAT(R) tool (31-33).
###end p 13
###begin p 14
The software computed three masks (background, fat, and nonfat tissues) using a fuzzy clustering segmentation. External and internal SAT boundaries were then defined by an active contour algorithm that exploited the previously computed masks as external force maps. A third contour was computed surrounding the area where VAT was present together with other tissues. VAT itself was assessed by the automated analysis of the signal histogram in the visceral region previously defined, by identifying the second peak of the signal histogram. This provided whole body volume (including the skeletal and soft tissues), total fat, SAT and VAT volumes, as well as VAT/SAT and fat/body volume ratios.
###end p 14
###begin title 15
Liver lipid measurements
###end title 15
###begin p 16
Localized 1H MRS of the liver was acquired on the GE Excite 1.5T MRI scanner. The liver slice with the largest gross dimensions was chosen for the MRS study. MRS for water and fat quantification was accomplished using a point resolved spectroscopy sequence. After line broadening and phase and baseline correction, the peak area of the water at 4.77 ppm and fat resonance (FR) at 1.40 ppm were measured. Quantification of the fat content was done by comparing the area of the FR with that of the unsuppressed water. Spectroscopic data were processed using the NUTS software. Hepatic fat percentage was calculated by dividing (FR) by the sum of FR and peak area of water. This technique is highly reproducible, with a coefficient of variation <2% in slices studied on eight separate occasions.
###end p 16
###begin title 17
Determination of adipocyte cell size, HO-1, and CB1
###end title 17
###begin p 18
###xml 665 667 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:9925">goat</span>
###xml 761 767 <span type="species:ncbi:9986">rabbit</span>
###xml 1084 1089 <span type="species:ncbi:9796">horse</span>
###xml 1284 1289 <span type="species:ncbi:9796">horse</span>
###xml 1295 1299 <span type="species:ncbi:9925">goat</span>
###xml 1423 1434 <span type="species:ncbi:3704">horseradish</span>
Subcutaneous adipose tissue and renal, liver, and aortic visceral fat tissue collected from untreated ob mice and L-4F-treated ob mice (n = 8 mice per group) were prepared for morphological analysis. Samples were fixed in 4% paraformaldehyde for 24 h, cut into small pieces, and embedded in paraffin for histological analysis. The samples were cut by microtome (5 mum thick), mounted on D-polylisinated glass slides, deparaffinizated in xylene, and stained with hematoxylin and eosin for the evaluation of adipocyte size or processed for CB-1 or HO-1 immunohistochemistry. Immunostaining for CB-1 was carried out using a goat polyclonal anti-CB-1 primary antibody (22) (Santa Cruz Biotechnology, Santa Cruz, CA), and HO-1 immunostaining was carried out using a rabbit polyclonal anti-HO-1 primary antibody (Stressgen Bioreagents, Victoria, BC, Canada). For each experimental group, five sections per animal were stained. Sections were immersed in 3% hydrogen peroxide and diluted in methanol for 30 min to quench endogenous peroxidase activity. The sections were preincubated with 3% horse serum for 60 min followed by primary antibody anti-CB-1 diluted 1:125 for 2 h at 37degreesC. The sections were then washed in TBS (0.1 M), incubated 30 min at room temperature with biotinylated horse anti-goat immunoglobulin (Vector Laboratories, Burlingame, CA), and then incubated for 30 min at room temperature with avidin-biotin-horseradish peroxidase complex (ABC complex; Vector Laboratories, Burlingame, CA). The reaction product was visualized using hydrogen peroxide and diaminobenzidine (Sigma-Aldrich, St. Louis, MO) as the chromogen. All slides were dehydrated and mounted in DPX (Sigma-Aldrich). Negative controls for primary antibody with nonimmune serum revealed no signal.
###end p 18
###begin title 19
Determination of CB-1 and HO-1 fat
###end title 19
###begin p 20
CB-1 and HO-1 staining intensity was computed as integrated optical density (IOD). Digitally fixed images of the slices (n = 5 per animal) at 20x magnification were analyzed using an optical microscope equipped with an image analyzer (Image Pro Plus; Immaginie Computer, Milan, Italy). For quantitative analysis, IOD was calculated for arbitrary areas, measuring three fields with the same area for each section.
###end p 20
###begin title 21
Determination of adipocyte cell size
###end title 21
###begin p 22
###xml 262 263 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Digital images of adipose tissue sections were captured using a light microscope (Olympus) at 20x magnification. For each group, three fields from each of five different hematoxylin-eosin stained sections per animal were analyzed. Individual adipocyte areas (mum2) within each field were determined using image analysis software (Image Pro Plus). For the quantitative analysis, adipocyte areas were calculated in arbitrary fields, measuring 50 adipocytes for each section.
###end p 22
###begin title 23
Western blot analysis of liver, kidney, and adipocyte stem cells for HO-1, AMPK, pAMPK, AKT, pAKT, and insulin receptor phosphorylation
###end title 23
###begin p 24
###xml 533 534 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 870 872 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 874 876 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 878 880 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 176 181 <span type="species:ncbi:10090">mouse</span>
At sacrifice, subcutaneous and visceral fat in the abdomen (the visible mesenteric fat and fat around the liver, kidney, spleen, and the heart) were dissected, pooled for each mouse, and used to isolate adipocyte stem cells. Specimens were stored at -140degreesC until assayed. Frozen liver, kidney, heart, and fat tissues were pulverized under liquid nitrogen and placed in a homogenization buffer [mmol/l: 10 phosphate buffer, 250 sucrose, 1 EDTA, 0.1 PMSF, and 0.1% (v/v) tergitol, pH 7.5]. Homogenates were centrifuged at 27,000 g for 10 min at 4degreesC, supernatant was isolated, and protein levels were visualized by immunoblotting with antibodies. Antibodies against AMPK, pAMPK, AKT, and pAKT were obtained from Cell Signaling Technology (Beverly, MA). Antibodies were prepared by dilution of HO-1, pAMPK, pAKT, and insulin receptor as we described previously (23, 25, 26).
###end p 24
###begin title 25
Measurement of fiber diameter and fat deposits
###end title 25
###begin p 26
Serial sections (8 mum thick) were cut by cryostat and stained with hematoxylin-eosin for morphological evaluation (measurement of diameter) and analayzed for fat deposits with Oil Red O staining. Digital images were taken using a light microscope (Olympus) and then analyzed with a software program (Image-Pro Plus 4.5.1). Ten fibers from each muscle slice were randomly selected to estimate fiber diameter; fat deposits were evaluated through measurement of the percentage of Oil Red O stained areas in five fields per randomly selected muscle sections. A total of five sections per animal were analyzed.
###end p 26
###begin title 27
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Adipocyte mesenchymal stem cell isolation from SAT and VAT of lean, ob, and ob L-4F-treated mice
###end title 27
###begin p 28
###xml 166 168 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 320 322 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
To isolate mouse adipocyte mesenchymal stem cells (MSCs), adipose tissues were washed with PBS and digested at 37degreesC for 30 min with 0.075% type II collagenase (34). At 50% confluence, L-4F was added as indicated in the figure legends. HO-1 and adipogenesis were measured, with the latter using Oil Red O staining (25).
###end p 28
###begin title 29
Glucose tolerance test
###end title 29
###begin p 30
###xml 19 23 <span type="species:ncbi:10090">mice</span>
After a 12 h fast, mice were injected i.p. with glucose (2.0g/kg body weight). Blood samples were taken at various time points (0-120 min) for measurement of blood glucose levels.
###end p 30
###begin title 31
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human bone marrow-derived mesenchymal stem cells and adipocytes
###end title 31
###begin p 32
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
Frozen bone marrow mononuclear cells were purchased from Allcells (Emeryville, CA). After thawing the cells, mononuclear cells were cultured as previously described (23, 25, 26).
###end p 32
###begin title 33
###xml 30 35 <span type="species:ncbi:9606">human</span>
Adipogenic differentiation of human MSCs and effect of L-4F
###end title 33
###begin p 34
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 317 319 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 321 323 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 524 526 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 643 645 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 647 649 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Adipogenic differentiation of human MSCs was induced by incubation in an adipogenesis induction medium [DMEM-high glucose (35, 36), supplemented with 10 mug/ml of insulin, 1 mumol/L of dexamethasone, 0.2 mmol/L of indomethacin, 10% FBS, and 1% antibiotic-antimycotic solution]. The medium was changed every 3-4 days (35, 36) for vehicle and L4F. At 50% confluence, L-4F and vehicle solutions were added, and HO-1, adiponectin, pAMPK, pAKT, and adipogenesis were measured, the latter using Oil Red O as previously described (25). MSC-derived adipocytes were treated with L-4F, 7.5 muM LY294002, a dose effective in inhibiting P 1-3 Kinase/AKT (29, 30). Addition of L-4F or LY294002 to adipocyte stem cell culture does not affect cell viability as measured by trypan blue staining.
###end p 34
###begin title 35
The effect of L-4F and LY2940002 in cultured adipocyte stem cells on Oil Red O staining and lipid droplet size
###end title 35
###begin p 36
###xml 348 356 348 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ImagePro</italic>
For Oil Red O staining, 0.21% Oil Red O in 100% isopropanol (Sigma-Aldrich) was used. Briefly, adipocytes were fixed in 10% formaldehyde, washed in Oil Red O for 10 min, rinsed with 60% isopropanol (Sigma-Aldrich), eluted Oil Red O by adding 100% isopropanol for 10 min, and measured OD at 490 nm for 0.5 s reading. Cell size was measured using an ImagePro Analyzer (MediaCybernetics Corporation, Silver Springs, MD). The classification of the size of lipid droplets was as follows and is based on size by area (pixels): >200 pixels (large lipid droplets); <199 (small lipid droplets).
###end p 36
###begin title 37
Statistical analysis
###end title 37
###begin p 38
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 584 585 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical significance between experimental groups was determined by the Fisher method of analysis of multiple comparisons (P < 0.05 was regarded as significant). For comparison between treatment groups, the null hypothesis was tested by either a single-factor ANOVA for multiple groups or unpaired t-test for two groups. Data are presented as mean +/- SEM except for cell size and IOD for CB1, which are presented as mean +/- SD. Differences between experimental groups were evaluated with ANOVA with Bonferroni corrections. Statistical significance was regarded as significant at P < 0.05.
###end p 38
###begin title 39
RESULTS
###end title 39
###begin title 40
L-4F treatment reduces weight gain and fat content
###end title 40
###begin p 41
###xml 80 86 80 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1</bold>
###xml 80 86 80 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig"><bold>Fig. 1</bold></xref>
###xml 257 258 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 466 472 462 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
We examined the effect of L-4F treatment on body and fat appearance. As seen in Fig. 1, L-4F treatment visibly reduced weight gain in ob mice. The final weights after 6 weeks of vehicle or L-4F treatment were (53 +/- 2.9 g and 43.2 +/- 1.7 g, respectively, P < 0.05). The L-4F-mediated reduction of weight gain was reversible. When L-4F was discontinued at week 10, ob mice gained weight at a faster rate than ob vehicle treated animals (data not shown). As seen in Fig. 1, visceral fat in obese mice was decreased by L-4F treatment. This provided semiquantitative estimates of fat content, which was quantitated using MRI as described below.
###end p 41
###begin p 42
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 259 264 <span type="species:ncbi:10090">mouse</span>
Effect of L-4F on body weight and visceral fat content in lean and ob mice. A: Effect of L-4F administration on body appearance. Examples of subcutaneous and visceral fat (B) and dissected fat (C) from lean and ob mice. Representative photographs showing one mouse from each group after 6 weeks of treatment (n = 8).
###end p 42
###begin title 43
Effect of L-4F on fat content determined by MRI
###end title 43
###begin p 44
###xml 49 55 49 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 2</bold>
###xml 49 55 49 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig"><bold>Fig. 2</bold></xref>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 597 598 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 676 677 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 910 911 883 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 962 963 935 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1141 1143 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 1012 1016 <span type="species:ncbi:10090">mice</span>
###xml 1109 1113 <span type="species:ncbi:10090">mice</span>
MRI was used to quantify SAT and VAT. As seen on Fig. 2, global SAT and global VAT were significantly decreased by L4F, P < 0.05 and P < 0.01, respectively. Subcutaneous fat in ob mice was decreased from 5.13 +/- 0.78 to 3.21 +/- 45g, and visceral fat in obese mice was decreased from 8.82 +/- 0.49 to 6.13 +/- 0.69 g. The decrease in visceral fat was accompanied by a significant increase in adiponectin levels and a decrease in the levels of the inflammatory cytokine IL-1 beta. Prior to treatment, adiponectin levels in the ob mice were 2.73 +/- 0.51 mug/ml compared with 4.76 +/- 0.93 mug/ml (P < 0.029) in lean animals. L-4F treatment resulted in a significant increase (P < 0.01) in the levels of serum adiponectin 6.14 +/- 1.49 mug/ml in the ob mice. Obese mice exhibited a significant increase in serum IL-1beta levels (123 +/- 29 pg/ml) when compared with age-matched lean controls (48 +/- 31 pg/ml), P < 0.05. L-4F treatment resulted in a significant (P < 0.01) decrease in serum IL-1 levels in the ob mice (39 +/- 26 pg/ml) compared with 106 +/- 21 pg/ml in untreated ob to levels seen in the lean mice, confirming previous data (23).
###end p 44
###begin p 45
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
Effect of L-4F treatment on Global SAT and VAT as measured. A: Effect of L-4F treatment on global SAT and VAT as measured by MRI. B: Global fat was increased in ob mice compared with ob-L-4F-treated mice (* P < 0.01, n = 3).
###end p 45
###begin title 46
L-4F treatment on muscle weight and intramuscular Oil Red O staining
###end title 46
###begin p 47
###xml 160 166 154 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 3</bold>
###xml 160 166 154 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig"><bold>Fig. 3</bold></xref>
###xml 181 187 175 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 414 421 399 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3B</xref>
###xml 508 509 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 609 616 594 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3D</xref>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
###xml 548 552 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
The weight of gastrocnemius muscle in lean mice, untreated ob mice, and L-4F-treated ob mice was 393 +/- 46 mg, 350 +/- 52 mg, and 356 +/- 48 mg, respectively (Fig. 3). As shown in Fig. 3, L-4F treatment did not affect muscle fiber, fat content, or muscle diameter. The diameters of muscle fibers for the lean, ob untreated, and L-4F-treated mice were 50 +/- 4.7 mum, 53 +/- 4 mum, and 51 +/- 4 mum, respectively (Fig. 3B). Intramuscular lipid droplets were severalfold higher in ob compared with lean mice (P < 0.005) but were not different in ob mice treated with L-4F when compared with untreated ob mice (Fig. 3D).
###end p 47
###begin p 48
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 704 705 702 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
Effect of L-4F on gastrocnemius muscle fibril diameter and muscle weight. A: Hematoxylin eosin staining of gastrocnemius and Oil Red O staining within myofibril interstitial spaces in muscle cross section. Small arrow indicates extracellular fat deposits and large bar indicates intracellular fat deposits. Lean (A), ob fat (B), ob fat L-4F (C). A: The mean diameter of myofibril of the lean versus obese (P < 0.05). B: Muscle fibril diameter, arrow in lean, ob, and ob-L4F-treated mice. C: Muscle weight was measured as described in Materials and Methods. The results are expressed as mean +/- SEM, n = 4. D: Oil Red O muscle fat staining showing increased staining in ob mice and not reduced by L-4F (*P < 0.005).
###end p 48
###begin title 49
Effect of L-4F on adipocyte size
###end title 49
###begin p 50
###xml 103 109 103 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 4</bold>
###xml 103 109 103 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig"><bold>Fig. 4</bold></xref>
###xml 192 193 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 200 207 197 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4A</xref>
###xml 292 293 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 301 302 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 431 438 425 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4B</xref>
###xml 566 567 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 629 630 617 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
Histological examination of SAT and VAT revealed that adipocyte cell size was significantly decreased (Fig. 4). Adipocyte cell size in the subcutaneous fat of control ob mice was 52 +/- 14 mum2 x100 (Fig. 4A). Adipocyte cell size was significantly lower in L-4F-treated ob mice, 42 +/- 11 mum2 x 100 (P < 0.05). A similar reduction was seen with L-4F treatment in adipocyte cell size in visceral fat surrounding aortic fat tissue (Fig. 4B). Adipocyte cell size was proportionally lower in subcutaneous fat tissue. Adipocyte cell size in lean animals was 37 +/- 9 mum2 x 100 compared with lean mice treated with L-4F (26 +/- 7 mum2 x 100) (data not shown).
###end p 50
###begin p 51
###xml 365 366 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
Effect of L-4F on Subcutaneous (A) and visceral (B) fat in ob mice. Haematoxylin-eosin staining of subcutaneous (A) and visceral (B) fat in ob and L-4F-treated ob mice. Bars = 50 mum. Quantitative analysis of adipocyte size in subcutaneous fat and visceral fat surrounding the aorta of ob or L-4F-treated ob mice is displayed. Data are expressed as means +/- SD (* P < 0.05 vs. ob).
###end p 51
###begin title 52
Effect of L-4F on CB1 and HO-1 expression in adipocytes of visceral and subcutaneous tissues
###end title 52
###begin p 53
###xml 243 244 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 254 260 250 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 5</bold>
###xml 254 260 250 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig"><bold>Fig. 5</bold></xref>
###xml 440 441 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 451 457 443 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 547 553 539 545 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 6</bold>
###xml 547 553 539 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig"><bold>Fig. 6</bold></xref>
###xml 556 557 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 687 689 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 691 693 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 481 485 <span type="species:ncbi:10090">mice</span>
We examined the effect of L-4F treatment on CB1 expression in adipose tissue. The level of CB1 expression in SAT was significantly lower in L-4F-treated ob mice (595 +/- 119 in control ob mice compared with 334 +/- 98 in L-4F-treated ob mice; P < 0.05) (Fig. 5). Similarly, the level of CB1 expression in VAT was significantly lower in L-4F-treated ob mice (788 +/- 124 in control ob mice compared with 409 +/- 153 in L-4F treated ob mice; P < 0.05) (Fig. 5). L-4F treatment of ob mice significantly increased HO-1 expression in both SAT and VAT (Fig. 6) (P < 0.05). The increase in HO-1 expression has been shown to suppress the levels of inflammatory cytokines released by adipocytes (23, 25).
###end p 53
###begin p 54
###xml 259 260 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
Expression of CB-1 expression in subcutaneous fat and visceral fat surrounding aorta of ob mice. A: IOD of CB-1 expression in subcutaneous fat and visceral fat surrounding aorta of ob or L-4F-treated ob mice is displayed. Data are expressed as mean +/- SD (* P < 0.05 vs. obese mice). B: Effect of L-4F on CB1 levels in SAT and VAT.
###end p 54
###begin p 55
###xml 433 434 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
Effect of L-4F on HO-1 expression in subcutaneous fat and visceral fat surrounding aorta of ob mice. A: Immunohistochemistry staining for HO-1 of subcutaneous fat and visceral fat surrounding aorta of ob or L-4F-treated ob mice. Arrows indicate HO-1 immunoreactivity. Bars = 50 mum. B: IOD of HO-1 expression in subcutaneous fat and visceral fat surrounding aorta of ob or L-4F-treated ob mice. Data are expressed as means +/- SD (* P < 0.05 SAT and VAT).
###end p 55
###begin title 56
Effect of L-4F on hepatic lipid content
###end title 56
###begin p 57
###xml 194 200 194 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 7</bold>
###xml 194 200 194 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig"><bold>Fig. 7</bold></xref>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
MRI showed that fat constituted 40% of hepatic tissue in untreated ob mice but only 15% of hepatic tissue in ob mice treated with L-4F. For comparison, hepatic fat content in lean mice was <5% (Fig. 7).
###end p 57
###begin p 58
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Effect of L-4F on percentage of fat in the liver of ob mice measured by MRS. Analysis of lipid content percentage of fat was calculated as described in Materials and Methods (*P < 0.01 vs. obese, n = 3).
###end p 58
###begin title 59
Effect of L-4F on liver insulin receptor phosphorylation
###end title 59
###begin p 60
###xml 442 448 442 448 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 8</bold>
###xml 442 448 442 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig"><bold>Fig. 8</bold></xref>
###xml 725 726 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 811 817 811 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 687 691 <span type="species:ncbi:10090">mice</span>
###xml 719 723 <span type="species:ncbi:10090">mice</span>
###xml 805 809 <span type="species:ncbi:10090">mice</span>
Visceral fat depots drain into the portal circulation, resulting in the elevation of free fatty acids. This has been implicated in the genesis of impaired insulin signaling and decreased phosphorylation of insulin receptors. We therefore examined the effect of L-4F treatment on liver insulin receptor phosphorylation in untreated ob and lean mice. Phosphorylation of insulin receptors at sites Tyr-972 and Tyr-1146 was examined and shown in Fig. 8; insulin phosphorylation at sites 972 and 1146 was significantly decreased in untreated ob mice compared with lean animals. Densitometry analysis showed that L-4F treatment increased the ratio of P-Tyr 972 and Tyr-1146 in L-4F-treated ob mice compared with untreated ob mice (P < 0.01), and the resulting levels were equal to or greater than those in lean mice (Fig. 8).
###end p 60
###begin p 61
Effect of L-4F on insulin receptor phosphorylation. A: Western blot and densitometry analysis of insulin receptor phosphorylation and actin proteins in liver of lean, ob, and ob-treated with L-4F. B: Quantitative densitometry evaluation of P-Tyr 972 and Tyr-1146 and actin proteins ratio was determined. Representative immunoblots are shown (n = 5).
###end p 61
###begin title 62
Effect of AKT kinase inhibitor on glucose levels
###end title 62
###begin p 63
###xml 121 128 121 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 9A</bold>
###xml 121 128 121 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig"><bold>Fig. 9A</bold></xref>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 289 296 289 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9A</xref>
###xml 461 468 461 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9A</xref>
###xml 962 968 962 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
Plasma glucose levels in ob mice treated with vehicle were significantly higher than those in ob mice treated with L-4F (Fig. 9A, upper panel, 0 time). Blood glucose levels in vehicle-treated ob mice were significantly (P < 0.001) elevated after glucose administration at all time points (Fig. 9A, upper panel). To clarify the role of pAKT and pAMPK as downstream signals in insulin sensitivity, we examined the effect of LY294002 on glucose levels. As seen in Fig. 9A, lower panel, LY294002 partially prevented the L-4F antihyperglycemic effect, resulting in increased glucose levels compared with L-4F-treated ob mice at the 0 time point. After glucose administration, glucose levels were elevated at all time points in the obese animals compared with the ob-L-4F-treated animals. Glucose levels in ob-L-4F-treated animals administered LY294002 remained elevated compared with ob-L-4F-treated animals at a level intermediate between the latter and ob animals (Fig. 9, lower panel).
###end p 63
###begin p 64
Effect of inhibition of pAKT by LY294002 on glucose tolerance and signaling. A: Effect of LY294002 [three times/week for 3 weeks, administered by intraperitoneal injection on glucose tolerance (IPGTT)] tests in obese, L-4F obese, was performed as described in Materials and Methods. The results are expressed mean +/- SEM, n = 3. B: Western blot of HO-1, adiponectin, pAKT, pAMPK, and actin proteins in kidney of ob, ob-treated with L-4F, and ob-treated with L-4F and LY294002. Representative immunoblots are shown (n = 4).
###end p 64
###begin title 65
Effect of L-4F on aorta AKT, pAKT, AMPK, and pAMPK
###end title 65
###begin p 66
###xml 11 18 11 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9B</xref>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 402 409 402 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9B</xref>
###xml 629 636 629 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9B</xref>
###xml 734 741 734 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9B</xref>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
As seen in Fig. 9B, AKT and AMPK levels in aorta tissue isolated from untreated ob mice were no different from that in lean mice or ob mice treated with L-4F. However, there were significant decreases in both pAKT and pAMPK in ob mice. Densitometry analysis showed that pAKT was increased significantly in ob mice treated with L-4F, compared with nontreated ob mice, P < 0.04. Additionally, as seen in Fig. 9B, LY294002 partially prevented the increase in L-4F-induced phosphorylation of AKT. The amount of nonphosphorylated AKT was unaffected by either L-4F or LY294002 treatment. Similar results were seen with AMPK and pAMPK (Fig. 9B). HO-1 levels were increased in ob-L-4F-treated animals. This was blunted by LY294002 treatment (Fig. 9B).
###end p 66
###begin title 67
Effect of L-4F and inhibitors of AKT on adipogenesis in adipocyte MSCs
###end title 67
###begin p 68
###xml 142 150 142 150 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 10A</bold>
###xml 142 150 142 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig"><bold>Fig. 10A</bold></xref>
###xml 155 156 155 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig"><bold>B</bold></xref>
###xml 341 342 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 454 462 453 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig">Fig. 10B</xref>
###xml 594 602 593 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig">Fig. 10C</xref>
###xml 688 696 687 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig">Fig. 10D</xref>
###xml 875 883 874 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig">Fig. 10C</xref>
###xml 885 886 884 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig">D</xref>
We also examined the effect of LY294002 on adipogenesis. Scan of lipid size of a representative experiment and Oil Red O staining is shown in Fig. 10A and B. L-4F decreased the levels of Oil Red O staining compared with control, while LY294002 (7.5 muM) increased Oil Red O staining in L-4F-treated cells. Thus, L-4F decreased adipogenesis (P < 0.05) as measured by Oil Red O staining, while LY294002 caused a significant increase in Oil Red O staining (Fig. 10B). Measurement of the size of the Oil Red O generated by adipocytes provides an indication of adipocyte regeneration and expansion (Fig. 10C). L-4F treatment decreased the number of large lipid droplets compared with control (Fig. 10D, upper panel). In contrast, supplementation of LY294002 alone or in the presence of L-4F significantly increased the large Oil Red O but decreased the number of small Oil Red O (Fig. 10C, D), compared with culture treated with LY294002 or control (untreated adipose cultures).
###end p 68
###begin p 69
###xml 425 426 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 456 457 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Effect of LY294002 on L-4F-mediated MSC-derived adipogenesis. A: Scan of lipid size of a representative experiment. B: Adipogenesis was measured as the relative absorbance of Oil Red O at day 10 after inducing adipogenesis as described in Materials and Methods. C: Measurement of number of lipid droplet size. D: Comparison of the effect of L-4F, LY294002, on number of lipid droplet sizes. Results are mean +/- SEM, n = 4 (*P < 0.05 vs. control medium; **P < 0.02 vs. LY294002 or control culture).
###end p 69
###begin title 70
DISCUSSION
###end title 70
###begin p 71
In this report, we demonstrate that L-4F decreased adipogenesis and adiposity. This is manifested by a decrease in both SAT and VAT, a decrease in hepatic lipid content, and the presence of increased numbers of adipocytes with smaller cell size. MRI and MRS showed that treatment with L-4F resulted in a reciprocal decrease in visceral fat with improvement in vascular dysfunction as determined by the levels of pAMPK, pAKT, and phosphorylation of insulin receptors. Thus, L-4F appears capable of reprogramming vascular tissue and adipocytes in a manner that results in the expression of a new phenotype that contains adipocytes of reduced cell size with restored insulin sensitivity. Four observations substantiate this conclusion.
###end p 71
###begin p 72
###xml 338 344 338 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 1091 1091 1091 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42"/>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 1196 1197 1196 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1199 1201 1199 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 1203 1205 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1207 1209 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 1073 1079 <span type="species:ncbi:9606">humans</span>
First, the L-4F-mediated prevention of visceral and subcutaneous fat accumulation, measured by MRI, is consistent with the observed decrease in hepatic lipid content. The decrease in lipid content is also consistent with the finding that L-4F treatment produced an elevation of the phosphorylation of insulin receptors at multiple sites (Fig. 8). The decrease in visceral and subcutaneous fat levels was paralleled by an increase in the number of smaller adipocytes, which are regarded as "healthy" insulin-sensitive adipocytes (37, 38). Thus, it appears that L-4F acts by preventing the adipocytes from increasing in size. Larger adipocytes appear to die off as their size increases (39), and the beneficial action of L-4F can be seen in lipid droplets that are smaller in size and with reduced hepatic lipid content (40). Abdominal fat mass is regarded as a predictor of cardiovascular risk (23, 25, 26, 40), which may be a result of obesity-mediated systemic inflammation with inflammatory cytokines TNF, IL-6, and IL-1, which are markedly elevated in obese rodents and humans (23, 25, 41-43). There is a direct proportionality of the degree of visceral adiposity and endothelial dysfunction (5, 23, 25, 40).
###end p 72
###begin p 73
###xml 226 228 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 230 232 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 339 340 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
Second, L-4F treatment decreased serum IL-1beta and CB1 receptor. The metabolic syndrome and obesity are characterized by increased serum levels of inflammatory cytokines, such as IL-1beta, which decrease insulin sensitivity (44, 45). CB1 receptors in mice increase hepatic lipogenic transcription factor SREBP-1 and fatty acid synthesis (7). Therefore, the L-4F-mediated decreases in the levels of IL-1beta and CB1 receptors may contribute to the observed increase in insulin sensitivity. In addition, downregulation of the peripheral endocannabinoid system, CB1, may contribute to the weight loss as well.
###end p 73
###begin p 74
###xml 211 212 211 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 213 214 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 674 674 674 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49"/>
###xml 674 674 674 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50"/>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1236 1238 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 422 426 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
Third, L-4F administration has been shown to increase HO-1 protein levels and adiponectin both in vitro and in vivo. Decreased levels of serum adiponectin are the result of an increase in the levels of ROS and H2O2, thereby contributing to the pathogenesis of insulin resistance (46, 47). Previous studies have shown that increased levels of HO-1 protein caused a marked increase in serum adiponectin levels in Zucker fat rats and ob mice (23, 25, 26). An increase in adiponectin levels is an indication of improvement in the metabolic syndrome that, in turn, leads to increased insulin sensitivity and a subsequent decrease in arterial disease and heart disease (37, 45, 48-51). This supports the concept that expansion of adipogenesis leads to an increased number of adipocytes of smaller cell size. Smaller adipocytes are considered to be healthy, insulin-sensitive adipocyte cells that are capable of producing adiponectin (37). While increases in obesity and diabetes are considered a risk factor for cardiovascular complications (45), improvement in the diabetic phenotype, including improved insulin sensitivity and glucose tolerance, may occur through increased preadipocyte differentiation and increased adiponectin secretion (37, 52).
###end p 74
###begin p 75
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 569 569 569 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56"/>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">57</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">58</xref>
###xml 691 691 691 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib59"/>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib60">60</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1280 1282 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 1284 1286 1284 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib61">61</xref>
###xml 1288 1290 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib62">62</xref>
###xml 1409 1411 1409 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib63">63</xref>
###xml 1411 1411 1411 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib64"/>
###xml 1412 1414 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib65">65</xref>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
Fourth, the remarkable action of L-4F treatment in increased pAKT, pAMPK, and phosphorylation of insulin receptors is associated in an improvement in glucose tolerance. Insulin resistance is an independent factor for the development of vascular dysfunction (53, 54). Therefore, L-4F treatment improves vascular function on the basis of increases in both insulin sensitivity and insulin receptor phosphorylation. Others have shown that increased phosphorylation of insulin receptors and vascular function may be a response to the increase in pAMPK and pAKT crosstalk (55-57). Further activation of pAMPK and pAKT increases glucose transport fatty acid oxidation and mitochondrial function (58-60). In this study, inhibition of pAKT by LY294002 administration in L-4F-treated mice reversed glucose tolerance and insulin sensitivity. We previously reported that LY294002 inhibition of the AKT pathways prevented HO-1 in ameliorating cell protection against ROS (30). However, LY294002 administration in vivo inhibited both AKT and AMPK and decreased glucose tolerance and insulin sensitivity. pAKT and AMPK act as fuel sensors in the regulation of energy balance, and the resultant crosstalk of AMPK-AKT has been shown to regulate nitric oxide bioavailability and vascular function (56, 61, 62). Furthermore, activated AMPK alone has been suggested as a therapeutic target to ameliorate endothelial dysfunction (63-65). Thus, the novel effect of L-4F on the HO-1-adiponectin-pAKT-pAMPK-module (i.e., an increase in HO-1) increases adiponectin, and the subsequent increase in AKT-AMPK crosstalk and signaling pathway provides a beneficial mechanistic basis for L-4F-mediated vascular protection. L-4F treatment offers great potential as a drug that could be employed therapeutically to address the metabolic derangements associated with obesity, the metabolic syndrome, and insulin-resistant diabetes to restore vascular function.
###end p 75
###begin title 76
Abbreviations
###end title 76
###begin p 77
FR, fat resonance
###end p 77
###begin p 78
HO, heme oxygenase
###end p 78
###begin p 79
IOD, integrated optical density
###end p 79
###begin p 80
i.p., intraperitoneally
###end p 80
###begin p 81
MRS, magnetic resonance spectroscopy
###end p 81
###begin p 82
MSC, mesenchymal stem cell
###end p 82
###begin p 83
ob, obese
###end p 83
###begin p 84
ROS, reactive oxygen species
###end p 84
###begin p 85
SAT, subcutaneous fat tissue
###end p 85
###begin p 86
SREBP-1, sterol-regulatory element binding protein-1
###end p 86
###begin p 87
VAT, visceral fat tissue
###end p 87
###begin p 88
The authors are indebted to Dr. Attallah Kappas and the Beatrice Renfield Foundation for their support. Ms. Daniele DeMarchi and Dr. Alessandro Pingipore are well appreciated for valuable help in the acquisition of Magnetic Resonance data.
###end p 88
###begin p 89
###xml 27 56 27 56 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 64 73 64 73 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">DK-068134</grant-num>
###xml 75 83 75 83 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">HL-55601</grant-num>
###xml 89 97 89 97 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">HL-34300</grant-num>
###xml 115 165 115 165 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">CNR Medical Department and Cardiopulmonary Project</grant-sponsor>
###xml 178 194 178 194 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Scuola Sant'Anna</grant-sponsor>
This work was supported by National Institutes of Health Grants DK-068134, HL-55601, and HL-34300 (N.G.A.), by the CNR Medical Department and Cardiopulmonary Project, and by the Scuola Sant'Anna.
###end p 89
###begin p 90
This work was presented in part at the American Heart Association, November, 2009.
###end p 90

